4.8 Editorial Material

Two-in-One Designer Antibodies

Journal

SCIENCE
Volume 323, Issue 5921, Pages 1567-1568

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1172253

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Alba Matas-Cespedes, Anna Vidal-Crespo, Vanina Rodriguez, Neus Villamor, Julio Delgado, Eva Gine, Heleia Roca-Ho, Pablo Menendez, Elias Campo, Armando Lopez-Guillermo, Dolors Colomer, Gael Roue, Adrian Wiestner, Paul W. H. I. Parren, Parul Doshi, Jeroen Lammerts van Bueren, Patricia Perez-Galan

CLINICAL CANCER RESEARCH (2017)

Letter Hematology

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

Niels W. C. J. van de Donk, Tineke Casneuf, Alessandro Di Cara, Paul W. Parren, Sonja Zweegman, Berris van Kessel, Henk M. Lokhorst, Saad Z. Usmani, Sagar Lonial, Paul G. Richardson, Christopher Chiu, Tuna Mutis, Inger S. Nijhof, A. Kate Sasser

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Letter Immunology

Response to Comment on Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

Patrick J. Engelberts, Esther C. W. Breij, T. Valerius, J. Schuurman, Paul W. H. I. Parren, F. J. Beurskens

JOURNAL OF IMMUNOLOGY (2018)

Article Biochemistry & Molecular Biology

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Julia Boshuizen, Louise A. Koopman, Oscar Krijgsman, Aida Shahrabi, Elke Gresnigt-van den Heuvel, Maarten A. Ligtenberg, David W. Vredevoogd, Kristel Kemper, Thomas Kuilman, Ji-Ying Song, Nora Pencheva, Jens Thing Mortensen, Marnix Geukes Foppen, Elisa A. Rozeman, Christian U. Blank, Maarten L. Janmaat, David Satijn, Esther C. W. Breij, Daniel S. Peeper, Paul W. H. I. Parren

NATURE MEDICINE (2018)

Article Multidisciplinary Sciences

Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement

Deniz Ugurlar, Stuart C. Howes, Bart-Jan de Kreuk, Roman I. Koning, Rob N. de Jong, Frank J. Beurskens, Janine Schuurman, Abraham J. Koster, Thomas H. Sharp, Paul W. H. I. Parren, Piet Gros

SCIENCE (2018)

Article Hematology

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. Parren, Ronald P. Taylor

HAEMATOLOGICA (2019)

Article Chemistry, Multidisciplinary

Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces

Juergen Strasser, Rob N. de Jong, Frank J. Beurskens, Guanbo Wang, Albert J. R. Heck, Janine Schuurman, Paul W. H. I. Parren, Peter Hinterdorfer, Johannes Preiner

NANO LETTERS (2019)

Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert, Paul W. H. I. Parren

NATURE REVIEWS DRUG DISCOVERY (2019)

Article Cell Biology

Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies

Cynthia S. M. Kramer, Marry E. I. Franke-van Dijk, Ashley J. Priddey, Tamas Pongracz, Elena Gnudi, Helena Car, Gonca E. Karahan, Els van Beelen, Chalana C. C. Zilvold-van den Oever, Hendrik J. Rademaker, Noortje de Haan, Manfred Wuhrer, Vasilis Kosmoliaptsis, Paul W. H. I. Parren, Arend Mulder, Dave L. Roelen, Frans H. J. Claas, Sebastiaan Heidt

Article Biochemistry & Molecular Biology

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Joost Neijssen, Rosa M. F. Cardoso, Kristen M. Chevalier, Luus Wiegman, Thomas Valerius, G. Mark Anderson, Sheri L. Moores, Janine Schuurman, Paul W. H. Parren, William R. Strohl, Mark L. Chiu

Summary: This study focused on developing a bispecific antibody targeting EGFR and MET pathways to overcome resistance to targeted therapies in nonsmall cell lung cancer patients. By sequentially screening a panel of BsAbs and selecting the optimal bispecific molecule, amivantamab was generated and demonstrated superior antitumor activity in preclinical models. The unique mode of action of amivantamab may provide benefits to patients with malignancies associated with aberrant EGFR and MET signaling.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Multidisciplinary Sciences

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis

Dana L. E. Vergoossen, Jaap J. Plomp, Christoph Gstottner, Yvonne E. Fillie-Grijpma, Roy Augustinus, Robyn Verpalen, Manfred Wuhrer, Paul W. H. Parren, Elena Dominguez-Vega, Silvere M. van der Maarel, Jan J. Verschuuren, Maartje G. Huijbers

Summary: This study demonstrates that the process of Fab-arm exchange in IgG4 amplifies autoantibody pathogenicity in autoimmune diseases, such as muscle-specific kinase (MuSK) myasthenia gravis. Monovalent anti-MuSK IgG4 antibodies were found to cause rapid and severe muscle weakness, indicating functional monovalency as a pathogenic mechanism in IgG4-mediated autoimmune diseases.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Review Biotechnology & Applied Microbiology

Avidity in antibody effector functions and biotherapeutic drug design

Simone C. Oostindie, Greg A. Lazar, Janine Schuurman, Paul W. H. Parren

Summary: This review discusses the role of avidity in eliciting antibody functional responses and current engineering strategies for manipulating avidity interactions in antibody-based therapies. Avidity, derived from multiple affinity interactions, is fundamental to all aspects of antibody biology and is crucial for enhancing or engineering novel properties in antibody biotherapeutics. Therapeutic antibody mechanisms of action are comprehensively reviewed with an emphasis on engineered optimizations and platforms, leading to a new wave of differentiated antibody drugs with tailored properties and promising improved treatment options for various diseases.

NATURE REVIEWS DRUG DISCOVERY (2022)

Article Chemistry, Analytical

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange

Ewald T. J. van den Bremer, Aran F. Labrijn, Ramon van den Boogaard, Patrick Priem, Kai Scheffler, Joost P. M. Melis, Janine Schuurman, Paul W. H. I. Parren, Rob N. de Jong

ANALYTICAL CHEMISTRY (2017)

Article Immunology

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9

Ronald P. Taylor, Margaret A. Lindorfer, Erika M. Cook, Frank J. Beurskens, Janine Schuurman, Paul W. H. I. Parren, Clive S. Zent, Karl R. VanDerMeid, Richard Burack, Masashi Mizuno, B. Paul Morgan

CLINICAL IMMUNOLOGY (2017)

Article Chemistry, Analytical

Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry

Guanbo Wang, Rob N. de Jong, Ewald T. J. van den Bremer, Paul W. H. I. Parren, Albert J. R. Heck

ANALYTICAL CHEMISTRY (2017)

No Data Available